CO6241154A2 - "NEW COMPOUNDS WITH AGONIST OR ANTAGONIST ACTION OF THE RECEIVER 1 VAINILLOIDE 1 (VR1 / TRPV1) \" - Google Patents
"NEW COMPOUNDS WITH AGONIST OR ANTAGONIST ACTION OF THE RECEIVER 1 VAINILLOIDE 1 (VR1 / TRPV1) \"Info
- Publication number
- CO6241154A2 CO6241154A2 CO09118505A CO09118505A CO6241154A2 CO 6241154 A2 CO6241154 A2 CO 6241154A2 CO 09118505 A CO09118505 A CO 09118505A CO 09118505 A CO09118505 A CO 09118505A CO 6241154 A2 CO6241154 A2 CO 6241154A2
- Authority
- CO
- Colombia
- Prior art keywords
- vainilloide
- trpv1
- agonist
- receiver
- new compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
1.- Compuestos sustituidos de la fórmula general Ien la cual n indica 0, 1, 2, 3 ó 4; R1 y R2 juntos indican un residuo que se selecciona del grupo que consiste de -CH=N-NH-; -CH=N-NR71; -S-C(=S)-NH-; -O-C(=S)-NH-; -S-C(=O)-NH-; -O-C(=O)-NH-; -S-C(=S)-NR63-; -O-C(=S)-NR63-; -S-C(=O)-NR63-; -O-C(=O)-NR63-; -S-CH=N-; -S-CR29=N-; -N=CH-O-; -N=CR30-O-; -NH-C(=O)-NH-; -NH-C(=S)-NH-; -NR66-C(=O)-NR65-; -NR66-C(=S)-NR65; -O-CH2-C(=O)-NH-; -O-CH2-O-; -O-CH2-CH2-O-; -O-CH2-CH2-CH2-O-; y -O-CH2-CH2-NH- y -CH=CH-N=CH-, el cual está unido en cualquier dirección deseada a la estructura original, o R2 y R3 juntos indican un residuo que se selecciona del grupo que consiste de -CH=N-NH-; -CR28=N-NH-; -CH=N-NR62-; -CR28=N-NR62-; -S-C (=S) -NH-; -O-C (=S) -NH-; -S- C(=O)-NH-; -O-C(=O)-NH-; -S-C(=S) -NR63-; -O-C(=S) -NR63-; -S-C(=O)-NR63-; -O-C (=O)-NR63-; -S-CH=N-; -S-CR29=N-; -N=CH-O-; -N=CR30-O-; -N=CH-NH-; -N=CH-NR64-; -NH-C(=O)-NH-; -NH-C(=S)- -NH-; -NR66-C(=O)-NR65-; -NR66-C(=S)-NR65-; -N=N-NH-; -N=N-NR67; -O-CH2-C (=O) -NH-; -O-CH2-O-; -CH2-CH2-NH-; -CH2-CH2-CH2-NH-; -CH2-C (=O)-NH-, -CH2-CH2-C(=O) -NH-; -O-CH2-CH2-O-; -O-CH2-CH2-CH2-O-; -N=N-CH=CH-; -N=CH-N=CH; -N=CH-CH=N-; -CH=CH-CH=N-; -CH=CH-N=CH-; -CH=N-N=CH-, -N=N-CR68=CR69-; -N=CR68-N=CR69; -N=CR68-CR69=N-; -CR68=CR69-CH=N-; -CR68CR69- N=CR70; -CR68=N-N=CR69- y -O-CH2-CH2-NH-, el cual está unido en cualquier dirección deseada a la estructura de origen, o R3 y R4 juntos indican un residuo que se selecciona del grupo que consiste de -CH=N-NH-; -CR28N-NH-; -CH=N-NR62-; -CR28=N-NR62-; -S-C(=S)-NH-; -O-C(=S)-NH-; -S-C(=O)-NH-; -O-C(=O)-NH-; -O-C(=O)-NH-; -S-C(=S)-NR63-; -O-C(=S)-NR63-; -S-C(=O)-NR63-; -O-C(=O)-NR63-; -S-CH=N-; -S-CR29=N-; -N=CH-O-; -N=CR30-O-; -N=CH-NH-; -N=CH-NR64-; -NH-C(=O)-NH-; -NH-C(=S)-NH-; -NR66-C(=O)-NR65-; ...1.- Substituted compounds of the general formula I in which n indicates 0, 1, 2, 3 or 4; R1 and R2 together indicate a residue that is selected from the group consisting of -CH = N-NH-; -CH = N-NR71; -S-C (= S) -NH-; -O-C (= S) -NH-; -S-C (= O) -NH-; -O-C (= O) -NH-; -S-C (= S) -NR63-; -O-C (= S) -NR63-; -S-C (= O) -NR63-; -O-C (= O) -NR63-; -S-CH = N-; -S-CR29 = N-; -N = CH-O-; -N = CR30-O-; -NH-C (= O) -NH-; -NH-C (= S) -NH-; -NR66-C (= O) -NR65-; -NR66-C (= S) -NR65; -O-CH2-C (= O) -NH-; -O-CH2-O-; -O-CH2-CH2-O-; -O-CH2-CH2-CH2-O-; and -O-CH2-CH2-NH- and -CH = CH-N = CH-, which is attached in any desired direction to the original structure, or R2 and R3 together indicate a residue that is selected from the group consisting of -CH = N-NH-; -CR28 = N-NH-; -CH = N-NR62-; -CR28 = N-NR62-; -S-C (= S) -NH-; -O-C (= S) -NH-; -S- C (= O) -NH-; -O-C (= O) -NH-; -S-C (= S) -NR63-; -O-C (= S) -NR63-; -S-C (= O) -NR63-; -O-C (= O) -NR63-; -S-CH = N-; -S-CR29 = N-; -N = CH-O-; -N = CR30-O-; -N = CH-NH-; -N = CH-NR64-; -NH-C (= O) -NH-; -NH-C (= S) - -NH-; -NR66-C (= O) -NR65-; -NR66-C (= S) -NR65-; -N = N-NH-; -N = N-NR67; -O-CH2-C (= O) -NH-; -O-CH2-O-; -CH2-CH2-NH-; -CH2-CH2-CH2-NH-; -CH2-C (= O) -NH-, -CH2-CH2-C (= O) -NH-; -O-CH2-CH2-O-; -O-CH2-CH2-CH2-O-; -N = N-CH = CH-; -N = CH-N = CH; -N = CH-CH = N-; -CH = CH-CH = N-; -CH = CH-N = CH-; -CH = N-N = CH-, -N = N-CR68 = CR69-; -N = CR68-N = CR69; -N = CR68-CR69 = N-; -CR68 = CR69-CH = N-; -CR68CR69- N = CR70; -CR68 = NN = CR69- and -O-CH2-CH2-NH-, which is attached in any desired direction to the source structure, or R3 and R4 together indicate a residue that is selected from the group consisting of -CH = N-NH-; -CR28N-NH-; -CH = N-NR62-; -CR28 = N-NR62-; -S-C (= S) -NH-; -O-C (= S) -NH-; -S-C (= O) -NH-; -O-C (= O) -NH-; -O-C (= O) -NH-; -S-C (= S) -NR63-; -O-C (= S) -NR63-; -S-C (= O) -NR63-; -O-C (= O) -NR63-; -S-CH = N-; -S-CR29 = N-; -N = CH-O-; -N = CR30-O-; -N = CH-NH-; -N = CH-NR64-; -NH-C (= O) -NH-; -NH-C (= S) -NH-; -NR66-C (= O) -NR65-; ...
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102007018149A DE102007018149A1 (en) | 2007-04-16 | 2007-04-16 | Substituted compound for producing pharmaceuticals for treating or prophylaxis of pain, nerve injuries, respiratory disorder, has general formulae |
EP2008002997 | 2008-04-15 | ||
US12/103,667 US8084484B2 (en) | 2007-04-16 | 2008-04-15 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6241154A2 true CO6241154A2 (en) | 2011-01-20 |
Family
ID=41360190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09118505A CO6241154A2 (en) | 2007-04-16 | 2009-10-22 | "NEW COMPOUNDS WITH AGONIST OR ANTAGONIST ACTION OF THE RECEIVER 1 VAINILLOIDE 1 (VR1 / TRPV1) \" |
Country Status (14)
Country | Link |
---|---|
JP (1) | JP2010523727A (en) |
KR (1) | KR20100016593A (en) |
CN (1) | CN101679370A (en) |
AU (1) | AU2008238250B2 (en) |
BR (1) | BRPI0810035A2 (en) |
CA (1) | CA2683461A1 (en) |
CO (1) | CO6241154A2 (en) |
EC (1) | ECSP099692A (en) |
IL (1) | IL201505A0 (en) |
MX (1) | MX2009011149A (en) |
NZ (1) | NZ580411A (en) |
RU (1) | RU2498982C2 (en) |
WO (1) | WO2008125342A2 (en) |
ZA (1) | ZA200907099B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007018149A1 (en) | 2007-04-16 | 2008-10-23 | Grünenthal GmbH | Substituted compound for producing pharmaceuticals for treating or prophylaxis of pain, nerve injuries, respiratory disorder, has general formulae |
US8946204B2 (en) | 2009-05-07 | 2015-02-03 | Gruenenthal Gmbh | Substituted phenylureas and phenylamides as vanilloid receptor ligands |
NZ595759A (en) | 2009-05-07 | 2014-03-28 | Gruenenthal Chemie | Substituted phenylureas and phenylamides as vanilloid receptor ligands |
WO2013013816A1 (en) | 2011-07-26 | 2013-01-31 | Grünenthal GmbH | Substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands |
AU2012289255A1 (en) | 2011-07-26 | 2014-01-30 | Grunenthal Gmbh | Substituted heterocyclic aza derivatives |
EP2776399A1 (en) * | 2011-11-09 | 2014-09-17 | Grünenthal GmbH | Substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an n-containing group as vanilloid receptor ligands |
EP2822928B1 (en) * | 2012-03-05 | 2018-11-14 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic acetamides as kappa opioid receptor (kor) agonists |
CN105829287B (en) | 2013-12-20 | 2019-08-27 | 埃斯蒂文制药股份有限公司 | The active bridged piperazine derivatives of multiplex mode with anti-pain |
CN107721919B (en) * | 2017-10-30 | 2020-12-08 | 中国药科大学 | Phenyl quinoline TRPV1 antagonist as well as preparation method and application thereof |
KR102334947B1 (en) * | 2020-04-22 | 2021-12-06 | 주식회사 제이맥켐 | Benzimidazolone based cinnamamide derivatives as TRPV1 antagonists and a pharmaceutical composition for treating or preventing pain containing the same as an active ingredient |
RU2755206C1 (en) | 2020-05-20 | 2021-09-14 | Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) | Agent with prolonged analgesic action and medicinal product based thereon |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1451156A4 (en) * | 2001-11-27 | 2005-05-25 | Merck & Co Inc | 4-aminoquinoline compounds |
ATE420644T1 (en) * | 2002-02-20 | 2009-01-15 | Abbott Lab | CONDENSED AZABICYCLIC COMPOUNDS AS INHIBITORS OF THE VANILLOID RECEPTOR 1 (VR1) |
GB0206876D0 (en) * | 2002-03-22 | 2002-05-01 | Merck Sharp & Dohme | Therapeutic agents |
US6933311B2 (en) * | 2003-02-11 | 2005-08-23 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
WO2004097044A1 (en) * | 2003-04-29 | 2004-11-11 | Oxagen Limited | Method of diagnosins a genetic susceptibility for bone damage |
SE0301446D0 (en) * | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | New Compounds |
PT1632477T (en) * | 2003-06-12 | 2017-04-04 | Astellas Pharma Inc | Benzamide derivative or salt thereof |
US20050113576A1 (en) * | 2003-08-05 | 2005-05-26 | Chih-Hung Lee | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
GB0322016D0 (en) * | 2003-09-19 | 2003-10-22 | Merck Sharp & Dohme | New compounds |
WO2005044802A2 (en) * | 2003-11-08 | 2005-05-19 | Bayer Healthcare Ag | Tetrahydro-quinolinylurea derivatives as vrl antagonists |
WO2005073193A1 (en) * | 2004-01-23 | 2005-08-11 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
DE102005023943A1 (en) * | 2005-05-20 | 2006-11-23 | Grünenthal GmbH | Pentafluorosulfanyl-substituted compound and its use for the preparation of medicaments |
EP2016065B1 (en) * | 2005-12-28 | 2012-09-19 | Vertex Pharmaceuticals Incorporated | 1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropane-carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis |
-
2008
- 2008-04-16 KR KR1020097023887A patent/KR20100016593A/en not_active Application Discontinuation
- 2008-04-16 CN CN200880020483A patent/CN101679370A/en active Pending
- 2008-04-16 RU RU2009142023/04A patent/RU2498982C2/en not_active IP Right Cessation
- 2008-04-16 NZ NZ580411A patent/NZ580411A/en not_active IP Right Cessation
- 2008-04-16 MX MX2009011149A patent/MX2009011149A/en active IP Right Grant
- 2008-04-16 JP JP2010503397A patent/JP2010523727A/en not_active Ceased
- 2008-04-16 BR BRPI0810035A patent/BRPI0810035A2/en not_active IP Right Cessation
- 2008-04-16 CA CA002683461A patent/CA2683461A1/en not_active Abandoned
- 2008-04-16 AU AU2008238250A patent/AU2008238250B2/en not_active Ceased
- 2008-04-16 WO PCT/EP2008/003027 patent/WO2008125342A2/en active Application Filing
-
2009
- 2009-10-12 ZA ZA2009/07099A patent/ZA200907099B/en unknown
- 2009-10-14 IL IL201505A patent/IL201505A0/en unknown
- 2009-10-16 EC EC2009009692A patent/ECSP099692A/en unknown
- 2009-10-22 CO CO09118505A patent/CO6241154A2/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
IL201505A0 (en) | 2010-05-31 |
CA2683461A1 (en) | 2008-10-23 |
ECSP099692A (en) | 2009-11-30 |
WO2008125342A3 (en) | 2009-01-15 |
RU2009142023A (en) | 2011-05-27 |
AU2008238250B2 (en) | 2013-01-24 |
CN101679370A (en) | 2010-03-24 |
AU2008238250A1 (en) | 2008-10-23 |
KR20100016593A (en) | 2010-02-12 |
WO2008125342A2 (en) | 2008-10-23 |
BRPI0810035A2 (en) | 2016-07-26 |
NZ580411A (en) | 2012-06-29 |
RU2498982C2 (en) | 2013-11-20 |
ZA200907099B (en) | 2013-03-27 |
MX2009011149A (en) | 2009-10-30 |
JP2010523727A (en) | 2010-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6241154A2 (en) | "NEW COMPOUNDS WITH AGONIST OR ANTAGONIST ACTION OF THE RECEIVER 1 VAINILLOIDE 1 (VR1 / TRPV1) \" | |
AR063813A1 (en) | PROGESTERONE RECEIVER ANTAGONISTS | |
CO6220949A2 (en) | PIRAZOLIC DERIVATIVES AS INHIBITORS OF THE 11 BETA -HSD1 | |
CL2011003347A1 (en) | Pharmaceutical composition comprising a conjugate, corresponding to hydrocodone benzoate; and use in the treatment of a disease, disorder or condition mediated by the binding of an opioid to opioid receptors. | |
BRPI0910182B8 (en) | compound of formula (I), pharmaceutical composition and use of a compound | |
ATE524466T1 (en) | 3-AZABICYCLOÄ3.3.0ÜOCTANE COMPOUNDS | |
CU23818A3 (en) | PROGESTERONE RECEIVER ANTAGONISTS | |
CR9459A (en) | BENZODIOXAN AND BENZODIOXOLAN DERIVATIVES AND USES OF THE SAME | |
ATE429427T1 (en) | PYRIMIDINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | |
UY28766A1 (en) | ADDITIONAL HETEROPOLYCLIC COMPOUNDS AND THEIR USE AS ANTAGONISTS OF THE METABOTROPIC GLUTAMATE RECEIVER | |
AR064735A1 (en) | GPCR AGONISTS AND PHARMACEUTICAL COMPOSITION BASED ON THE COMPOUND | |
PE20141827A1 (en) | PROTEIN INHIBITORS KINASES | |
CO6321239A2 (en) | DERIVATIVES OF ISOXAZOL AND ITS USE AS POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | |
ATE502936T1 (en) | 2, 6-DI-(HETERO-)ARYL-4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | |
PE20120578A1 (en) | S1P5 RECEPTOR AGONISTS AND ANTAGONISTS, AND METHODS OF USE OF THE SAME | |
DE602007005241D1 (en) | Purin derivatives as A2A receptor agonists | |
PE20070438A1 (en) | DERIVATIVES OF 4-PHENYL-PYRIMIDINE-6-SUBSTITUTE-2-CARBONITRILE AS INHIBITORS OF CATEPSIN K AND CATEPSIN S | |
GT200500292A (en) | DERIVATIVES OF 2-AMIDO-4-FENILTIAZOL, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS | |
AR061520A1 (en) | DERIVATIVES OF CINAMOIL-PIPERAZINA | |
CO6140054A2 (en) | DIALQUILPHENYL COMPOUNDS WITH BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY AND MUSCARINIC RECEIVER ANTAGONIST | |
GT200900026A (en) | DERIVATIVES OF 5,6 -BISARIL-2-PIRIDIN-CARBOXAMIDA, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS AS ANTAGONISTS OF UROTENSIN II RECEPTORS | |
TW200740795A (en) | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | |
PE20121049A1 (en) | DERIVATIVES OF PIRAZINOOXAZEPINE | |
WO2008116185A3 (en) | Substituted pyrimidines as adenosine receptor antagonists | |
MY158747A (en) | Glucocorticoid receptor agonist comprising 2, 2, 4- trimethyl-6-phenyl-1,2-dihydroquinoline derivatives having substituted oxy group |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted |